Global Finance News
27 Mar 2026, 18:51
Sanofi announced that its cancer therapy Sarclisa in a subcutaneous formulation has received a positive recommendation from the European Medicines Agency’s CHMP for the treatment of multiple myeloma.
The recommendation is based on clinical data showing comparable efficacy, safety, and pharmacokinetics between the new subcutaneous version and the existing intravenous formulation. If approved, Sarclisa would become the first anticancer treatment delivered via an on-body injector in the EU, offering greater flexibility and convenience for patients and healthcare providers.
Studies also indicated higher patient and provider preference for the subcutaneous administration method, which uses a wearable injector designed to improve comfort and simplify treatment delivery.
A final regulatory decision is expected in the coming months, with the new formulation potentially expanding treatment options for patients with multiple myeloma across Europe.
The recommendation is based on clinical data showing comparable efficacy, safety, and pharmacokinetics between the new subcutaneous version and the existing intravenous formulation. If approved, Sarclisa would become the first anticancer treatment delivered via an on-body injector in the EU, offering greater flexibility and convenience for patients and healthcare providers.
Studies also indicated higher patient and provider preference for the subcutaneous administration method, which uses a wearable injector designed to improve comfort and simplify treatment delivery.
A final regulatory decision is expected in the coming months, with the new formulation potentially expanding treatment options for patients with multiple myeloma across Europe.
